•
Dec 31, 2022
Nkarta Q4 2022 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2022.
Key Takeaways
Nkarta reported its Q4 and full year 2022 financial results, highlighting progress in clinical trials for NKX101 and NKX019, and a year-end cash position of $354.9 million expected to fund operations into 2025.
Clinical updates on track for NKX101 in the first half of 2023 and NKX019 in full year 2023.
Year-end cash and cash equivalents totaled $354.9 million.
Cash runway anticipated to fund operations into 2025.
Nkarta plans to present additional results from its ongoing clinical trials of NKX101 and NKX019 in 2023.
Nkarta
Nkarta
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2025.